Recent News

• 04.25.2025 - Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
• 03.13.2025 - Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update
• 01.28.2025 - Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
• 01.10.2025 - Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6

Recent Filings

• 04.25.2025 - 8-K Current report
• 04.25.2025 - EX-99.1 EX-99.1
• 04.25.2025 - 424B4 Prospectus [Rule 424(b)(4)]
• 04.24.2025 - EFFECT Notice of Effectiveness
• 04.24.2025 - S-1/A General form for registration of securities under the Securities Act of 1933
• 04.23.2025 - FWP Filing under Securities Act Rules 163/433 of free writing prospectuses
• 04.23.2025 - EX-99.1 EX-99.1
• 04.23.2025 - 8-K Current report
• 04.22.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 03.28.2025 - DRS Draft Registration Statement